These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 17981926)

  • 1. Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
    McLerran D; Grizzle WE; Feng Z; Bigbee WL; Banez LL; Cazares LH; Chan DW; Diaz J; Izbicka E; Kagan J; Malehorn DE; Malik G; Oelschlager D; Partin A; Randolph T; Rosenzweig N; Srivastava S; Srivastava S; Thompson IM; Thornquist M; Troyer D; Yasui Y; Zhang Z; Zhu L; Semmes OJ
    Clin Chem; 2008 Jan; 54(1):44-52. PubMed ID: 17981926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.
    McLerran D; Grizzle WE; Feng Z; Thompson IM; Bigbee WL; Cazares LH; Chan DW; Dahlgren J; Diaz J; Kagan J; Lin DW; Malik G; Oelschlager D; Partin A; Randolph TW; Sokoll L; Srivastava S; Srivastava S; Thornquist M; Troyer D; Wright GL; Zhang Z; Zhu L; Semmes OJ
    Clin Chem; 2008 Jan; 54(1):53-60. PubMed ID: 18024530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.
    Adam BL; Qu Y; Davis JW; Ward MD; Clements MA; Cazares LH; Semmes OJ; Schellhammer PF; Yasui Y; Feng Z; Wright GL
    Cancer Res; 2002 Jul; 62(13):3609-14. PubMed ID: 12097261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
    Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
    J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.
    Semmes OJ; Feng Z; Adam BL; Banez LL; Bigbee WL; Campos D; Cazares LH; Chan DW; Grizzle WE; Izbicka E; Kagan J; Malik G; McLerran D; Moul JW; Partin A; Prasanna P; Rosenzweig J; Sokoll LJ; Srivastava S; Srivastava S; Thompson I; Welsh MJ; White N; Winget M; Yasui Y; Zhang Z; Zhu L
    Clin Chem; 2005 Jan; 51(1):102-12. PubMed ID: 15613711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.
    Yasui Y; Pepe M; Thompson ML; Adam BL; Wright GL; Qu Y; Potter JD; Winget M; Thornquist M; Feng Z
    Biostatistics; 2003 Jul; 4(3):449-63. PubMed ID: 12925511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic potential of serum proteomic patterns in prostate cancer.
    Bañez LL; Prasanna P; Sun L; Ali A; Zou Z; Adam BL; McLeod DG; Moul JW; Srivastava S
    J Urol; 2003 Aug; 170(2 Pt 1):442-6. PubMed ID: 12853795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.
    Qu Y; Adam BL; Yasui Y; Ward MD; Cazares LH; Schellhammer PF; Feng Z; Semmes OJ; Wright GL
    Clin Chem; 2002 Oct; 48(10):1835-43. PubMed ID: 12324514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach.
    Kmeťová Sivoňová M; Tatarková Z; Jurečeková J; Kliment J; Híveš M; Lichardusová L; Kaplán P
    Neoplasma; 2021 Jan; 68(1):154-164. PubMed ID: 32977723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preanalytical influences in clinical proteomic studies: raising awareness of fundamental issues in sample banking.
    Banks RE
    Clin Chem; 2008 Jan; 54(1):6-7. PubMed ID: 18160723
    [No Abstract]   [Full Text] [Related]  

  • 11. Proteomics in diagnosis of prostate cancer.
    Davalieva K; Polenakovic M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
    Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
    Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer.
    Malik G; Ward MD; Gupta SK; Trosset MW; Grizzle WE; Adam BL; Diaz JI; Semmes OJ
    Clin Cancer Res; 2005 Feb; 11(3):1073-85. PubMed ID: 15709174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
    Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer.
    Skytt A; Thysell E; Stattin P; Stenman UH; Antti H; Wikström P
    Int J Cancer; 2007 Aug; 121(3):615-20. PubMed ID: 17410539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Value of Circulating miR-324 for Prostate Cancer.
    Jin YY; Tong SQ; Tong M
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis.
    Cheng L; Zhou L; Tao L; Zhang M; Cui J; Li Y
    J Cancer Res Clin Oncol; 2008 Jul; 134(7):769-76. PubMed ID: 18202856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative protein markers in the sera of men with prostatic neoplasms.
    Lehrer S; Roboz J; Ding H; Zhao S; Diamond EJ; Holland JF; Stone NN; Droller MJ; Stock RG
    BJU Int; 2003 Aug; 92(3):223-5. PubMed ID: 12887471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.
    Giskeødegård GF; Hansen AF; Bertilsson H; Gonzalez SV; Kristiansen KA; Bruheim P; Mjøs SA; Angelsen A; Bathen TF; Tessem MB
    Br J Cancer; 2015 Dec; 113(12):1712-9. PubMed ID: 26633561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions.
    Le L; Chi K; Tyldesley S; Flibotte S; Diamond DL; Kuzyk MA; Sadar MD
    Clin Chem; 2005 Apr; 51(4):695-707. PubMed ID: 15695329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.